Аркадий Медведев - Системная реабилитология

327. Эберхард-Метцгер К. История медицины. — М.: Мир книги, 2008. — 48 с.

328. Эллиот В., Эллиот Д. Биохимия и молекулярная биология. Пер. с англ. — М.: Изд-во НИИ биомедицинской химии РАМН, 1999. — 373 с.

329. Ярмоненко С. П., Вайсон А. А. Радиобиология человека и животных. Учебное пособие. — М.: Высшая школа, 2004. — 549 с.

330. Agabegi S. S., Derby E.A., Ryer E, Mehta S., Mirarchi A.J. Step-up to Internal Medicine. — Lippincott Williams and Wilkins, 2004. — 512 р.

331. Beutler E.B., Coller B.S., Lichtman M.A. et al. Heamotology. Sixth Edition. — New York, 2001. — 1941 p.

332. Bjerrum L, Larsen J., Kragstrup J. Increased use of lipid-lowering agents after implementation of clinical guidelines in general practice // Ugeskr. Laeger. — 2003. — Vol. 164, N 2. — Р. 120—123.

333. Bloomgarden Z.T. Developments in diabetes and insulin resistance // Diabetes Care. — 2006. — Vol. 29. — P. 161—167.

334. Bochner B.S. Systemic activation of basophils and eosinophils: markers and consequences // J. Allergy Clin. Immunol. — 2000. — Vol. 5, N 2. — P. 292—302.

335. Brouillard P., Vikulla M. Vascular malformatiоn: localized defects in vascular morphogenesis / Clin. Genet. — 2003. — Vol. 63, N 5. -Р. 340—351.

336. Dimopoulos M.A., Ranayiotidis P., Moulopoulos L.A.. et al. Waldenstrom’s macroglobulinemia: clinical features, complications and management // J. Clin. Oncol. — 2000. — Vol. 18. — P. 214—225.

337. Handbook of Biomaterials Evaluation // Ed. A.F. von Recum. — N.Y.: Macmillan Publishing Company, 1986. — 611 p.

338. Hematology: basic principles and practice / Ed. R. Hofman et al. 3 rd ed. — Churchfull Livingstone, 2000. — 2584 p.

339. Ibrahim S., Keating M., Do K.A. et al. CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia // Blood. — 2001. — Vol. 98, N 1. — P. 181—186.

340. Ishiguro A., Suzuki Y., Mito M. et al. Elevation of serum thrombopoietin precedes thrombocytosis in acute infections / Br. J. Haematol. — 2002. — Vol. 116. — P. 612—618.

341. Jaffe E.S., Harris N.L., Stein H. et al. Pathology and genetics of tumors of heamotopoietic and lymphoid tissues. — Lion: IARC Press, 2001. — 357 p.

342. Larsen J., Andersen M., Bjerrum L. et al. Insufficient use of lipidlowering drugs and measurement of serum cholesterol among patients with a history of myocardial infarction // J. Cardiovasc. Risk. — 2003. — Vol. 10, N 1. — Р. 61—64.

343. Nearman Z.P., Wlodarski M., Jankowska A.M. et al. Immunogenetic factors determining the evolution of T-cell large granular lymphocytes leukaemia and associated cytopenias / Br. J. Haematol. — 2006. — Vol. 136. — P. 237—248.

344. Pearson T.A. The undertreatment of LDL-cholesterol: addressing the challenge // Int. J. Cardiol. — 2000. — Vol. 74, N 1. — Р. 23—28.

345. Pearson TC. The risk of thrombosis in essential thrombocythemia and polycythemia vera // Semin. Oncol. — 2002. — Vol. 29. — Suppl. 10. — P. 16—21.

346. Pileri S.A., Ascani S., Leoncini L. et al. Nodgkin’s lymphoma: the pathological viewpoint // J. Clin. Pathol. — 2002. — Vol. 55 -P. 162—176.

347. Pitiphat W. Plasma C-reactive protein in early pregnancy and preterm delivery // Am. J. Epidemiol. — 2005. — Vol. 162, N 11. — Р. 1108—1113.

348. Robak T. Monoclonal antibodies in the treatment of autoimmune cytopenias / Eur. J. Hematol. — 2004. — Vol. 72. — P. 79—88.

349. Summerskill W.S., Pope C. An exploratory qualitative study of the barriers to secondary prevention in the management of coronary heart disease // Family Pract. — 2002. — Vol. 19, N 6. — Р. 605—610.

350. Ujita K., Ohno K., Hashiguchi M. et al. Drug use evaluation of antidyslipidemic agents at a community hospital in Japan // Yakugaku Zasshi. — 2002. — Vol. 122, N 7. — Р. 499—506.